NICE gives limited approval for prasugrel

Justine Varieur Cadet | | Health Imaging | Screening
The National Institute for Health and Clinical Excellence (NICE) has issued approval for the marketing of prasugrel (Efient in EU/Effient in U.S.) from Eli Lilly and Daiichi Sankyo, with a few limitations.

According to NICE, prasugrel in combination with aspirin is now recommended as an option for preventing atherothrombotic events in people with acute coronary syndromes (ACS) having PCI, only when:
  • immediate primary PCI for STEMI is necessary; or
  • stent thrombosis has occurred during clopidogrel (Plavix from Bristol-Myers Squibb) treatment; or
  • the patient has diabetes mellitus.
However, the agency said that patients currently receiving prasugrel for treatment of ACS whose circumstances do not meet these criteria “should have the option to continue therapy until they and their clinicians consider it appropriate to stop.”

Justine Varieur Cadet

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.